Orthofix upgraded to Buy from Neutral at Roth MKM

Roth MKM analyst Jason Wittes upgraded Orthofix to Buy from Neutral with a price target of $20, up from $15, post the Q1 report. The stock’s valuation has remained significantly reduced since the management turnover in 2023 as investors look for signs of stability and better visibility on earnings, the analyst tells investors in a research note. The firm views Orthofix’s recent results and guidance as the consistent performance and outlook needed to justify a higher multiple.